세계 좌심이 폐쇄(LAAC) 디바이스 시장 규모는 2023년 12억 694만 달러에 달했습니다. 이 시장은 2024년부터 2030년까지 예측 기간 동안 11.45%의 연평균 복합 성장률(CAGR)로 성장하여 2030년까지 25억 6,470만 달러에 달할 것으로 예상됩니다. 좌심이 폐쇄(LAAC) 디바이스에 대한 수요는 주로 심방 세동, 허혈성 뇌졸중 및 심장 마비와 같은 심혈관 질환의 유병률 증가로 인해 강화되고 있습니다. 또한, 좌심이 폐쇄(LAAC) 디바이스 분야의 기술 발전 증가는 2024년부터 2030년까지 예측 기간 동안 좌심이 폐쇄(LAAC) 디바이스 시장의 성장에 기여하는 또 다른 중요한 요소입니다.
American Heart Association 2020이 제공한 자료에 따르면, 2010년 유럽에서는 55세 이상의 심방세동 환자 900만 명 이상이 심방세동을 앓고 있으며, 2060년까지 1,400만 명에 달할 것으로 추산됩니다. 또한, 같은 자료에 따르면 2050년까지 아시아에서 심방세동과 이와 관련된 뇌졸중이 약 7,200만 건이 발생할 것으로 예상하고 있습니다. 이처럼 고칼로리 식단, 흡연, 운동 부족 등 다양한 요인으로 인해 심방세동과 같은 심혈관 질환의 유병률이 증가함에 따라 심혈관 질환의 관리 및 치료의 필요성이 대두되고 있으며, 이는 좌심이 폐쇄(LAAC) 디바이스 시장의 긍정적인 성장을 가져옵니다.
세계보건기구(WHO)가 2021년 발표한 자료에 따르면, 2015년부터 2050년까지 전 세계 60세 이상 노인의 비율이 12%에서 22%로 두 배로 증가할 것으로 예상됩니다. 이러한 증가로 2050년에는 60세 이상 노인이 총 21억 명에 달할 것으로 예상됩니다. 또한 2030년에는 6명 중 1명이 60세 이상의 노인이 될 것입니다. 나이가 들어감에 따라 심장은 정상적인 노화 과정의 일환으로 다양한 구조적, 기능적 변화를 겪습니다. 이러한 변화는 심혈관계에 영향을 미치고 다양한 심혈관계 질환의 지속과 발병에 영향을 미칠 수 있습니다. 따라서 노인 인구 증가는 좌심이 폐쇄(LAAC) 디바이스 시장의 성장에 긍정적인 영향을 미칠 것으로 보입니다.
이 보고서는 세계 좌심이 폐쇄(LAAC) 디바이스 시장에 대해 조사했으며, 시장 개요와 함께 제품별/최종사용자별/지역별 동향, 시장 진출기업 프로파일 등의 정보를 제공합니다.
Left Atrial Appendage Closure Device Market By Product (Endocardial And Epicardial), End-User (Hospitals, Ambulatory Surgical Centers, And Others), and geography is expected to grow at a steady CAGR forecast till 2030 owing to the rising prevalence of cardiovascular disorders and increasing technological advancements in the domain of left atrial appendage closure devices
The Global Left Atrial Appendage Closure Device Market Was Valued At USD 1,206.94 Million In 2023, Growing At A Cagr Of 11.45% during the forecast period from 2024 to 2030 to reach usd 2,564.70 million by 2030. The demand for left atrial appendage closure devices is primarily being bolstered by the rising prevalence of cardiovascular disorders such as atrial fibrillation, ischemic strokes, and heart attacks. additionally, increasing technological advancement in the domain of left atrial appendage closure, is another key factor that is contributing to the growth of the left atrial appendage closure market during the forecast period from 2024-2030.
Left Atrial Appendage Closure Device Market Dynamics:
As per the data provided American Heart Association 2020, it was estimated that in Europe more than 9 million individuals, who were older than 55 years were suffering from atrial fibrillation in the year 2010, which is expected to reach 14 million by 2060. Additionally, the same source stated that by the year 2050, there will be about 72 million cases of atrial fibrillation and associated strokes in Asia. Thus the rising prevalence of cardiovascular disorders such as atrial fibrillation due to various factors including high-calorie diet, smoking, and lack of physical inactivity, will create a need for the management and treatment of cardiovascular disorders, thus resulting in the positive growth of the left atrial appendage closure device market.
According to data provided by the World Health Organization in 2021, the percentage of people aged 60 years and above is expected to double from 12% to 22% between 2015 and 2050, globally. This increase will eventually lead to a total of 2.1 billion people aged 60 years or above by the year 2050. Additionally, by the year 2030, 1 in 6 people will be aged 60 years or above. As the age increases the heart undergoes various structural and functional changes as a part of the normal aging process. These changes can affect the cardiovascular system, potentially contributing to the persistence or development of various cardiovascular disorders. Therefore, the rise in the geriatric population will positively influence the growth of the left atrial appendage closure device market.
However, the high cost associated with the left atrial appendage closure devices and the presence of alternate treatment methods in the market, are some of the key constraints that may limit the growth of the left atrial appendage closure device market.
Left Atrial Appendage Closure Device Market Segment Analysis:
Left Atrial Appendage Closure Device market by Product (Endocardial and Epicardial), End-user (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
In the product segment of the left atrial appendage closure device market, the endocardial category is estimated to amass a significant revenue share in the left atrial appendage closure device market in 2023. As technology is evolving, endocardial devices are becoming more sophisticated, offering improved efficacy and safety profiles compared to other devices. Additionally, endocardial LAA devices offers benefits such as reduced invasiveness, shorter recovery times, and fewer complications compared to the alternative methods. Further, Endocardial LAA devices, when compared with other products are very effective in managing stroke and reducing bleeding.
Thus, the various advantages provided by the endocardial LAA devices, will tend to increase the demand of the segment and in turn propelling the growth of the left atrial appendage closure devices during the forecast period.
North America Is Expected To Dominate The Overall Left Atrial Appendage Closure Device Market:
North America is expected to account for the highest proportion of the Left Atrial Appendage Closure Device Market in 2023, out of all regions. This is due to the high prevalence of cardiovascular disorders in the region. Additionally, rising technological advancements in the domain of left atrial appendage closure devices, and a highly viable market in terms of product development, and launches are some of the factors driving the growth of the left atrial appendage closure device market in North America.
As per the data provided American Heart Association 2020, it was estimated that at least 3 to 6 million people are suffering from atrial fibrillation and which is expected to reach 6 to 16 million by the year 2050 in the United States. Additionally, according to the data provided by the Centers for Disease Control and Prevention 2023, it was estimated that around 60 million women (44%), were living with some form of heart disease every year on average in the United States. Thus, with the rising prevalence of various cardiovascular disorders fueled by various factors such as sedentary lifestyle, consumption of alcohol and tobacco, and obesity, will create a need for the management and treatment of these diseases, thus eventually contributing to the positive growth of the left atrial appendage closure device market in the United States, which will eventually propel the left atrial appendage closure device market in North America.
Further, various key product launches and product approvals in the region are some of the other factors that are influencing the positive growth of the market in North America. For instance in August 2021, the Food and Drug Administration granted approval to Abbott for its Amplatzer Amulet Left Atrial Appendage Closure occluder, which is specially designed to treat individuals with atrial fibrillation who are at risk of ischemic stroke.
Therefore, the factors mentioned above, and the increasing product launches and product approvals in the region are some of the important factors that are thereby responsible for driving the overall market for Left Atrial Appendage Closure Devices in North America during the forecast period.
Left Atrial Appendage Closure Device Market Key Players:
Some of the key market players operating in the Left Atrial Appendage Closure Device market include Boston Scientific Corporation, Johnson & Johnson, Abbott Laboratories, Articure, Occlutech, Cardia Inc., Lifetech Scientific Corporation, Lepu Medical Technology, Biosense Webster, SentreHEART, Inc., Conformal Medical, and Lifetech Scientific Corporation
Recent Developmental Activities In The Left Atrial Appendage Closure Device Market:
Key Takeaways From The Left Atrial Appendage Closure Device Market Report Study
Target Audience Who Can Be Benefited From This Left Atrial Appendage Closure Device Market Report Study
Frequently Asked Questions For The Left Atrial Appendage Closure Device Market:
Left Atrial Appendage Closure (LAA) Devices are medical devices designed to reduce the risk of stroke in patients with atrial fibrillation (AF) who are at high risk of stroke and are unable to tolerate long-term anticoagulation therapy.
The global Left Atrial Appendage Closure Device Market was valued at USD 1,206.94 million in 2023, growing at a CAGR of 11.45% during the forecast period from 2024 to 2030 to reach USD 2,564.70 million by 2030.
The Left Atrial Appendage Closure Device market is slated to witness prosperity owing to factors such as the rising prevalence of cardiovascular disorders such as atrial fibrillation, ischemic strokes, and heart attacks. Additionally, increasing technological advancement in the domain of Left Atrial Appendage Closure, is another key factor which is contributing to the growth of the Left Atrial Appendage Closure market during the forecast period from 2024-2030.
Some of the key market players operating in the Left Atrial Appendage Closure Device market Boston Scientific Corporation, Johnson & Johnson, Abbott Laboratories, Articure, Occlutech, Cardia Inc., Lifetech Scientific Corporation, Lepu Medical Technology, Biosense Webster, SentreHEART, Inc., Conformal Medical and Lifetech Scientific Corporation.
North America is expected to dominate the overall Left Atrial Appendage Closure Device market during the forecast period, 2024 to 2030. This is due to the presence high prevalence of cardiovascular disorders in the region. Additionally, rising technological advancements, presence of major players in the region, and a highly viable market in terms of product development, and launches are some of the factors driving the growth of the Left Atrial Appendage Closure Device Market in North America.